Pfizer's once-monthly injectable obesity treatment, PF-3944, demonstrated significant weight loss in a Phase 2b study, positioning the pharmaceutical giant to challenge market leaders Novo Nordisk and Eli Lilly. The company plans an expansive Phase 3 program starting in 2026.
Google's parent company closed 2025 with robust profit and revenue, powered by surging cloud demand. Yet, a sharp increase in planned capital expenditure for AI infrastructure spooked investors, sending shares lower and signaling a new, more uncertain investment phase for the tech giant.
Former President Donald Trump has reversed course, stating he will not involve himself in the fierce bidding battle between Netflix and the Paramount Skydance consortium for key Warner Bros. Discovery assets, leaving the decision to regulatory bodies.
Despite a decade of closures, major banks are reinvesting in branches—not as transaction centers, but as data-driven advisory hubs. Advanced analytics is key to personalizing service, improving profitability, and serving community needs in an increasingly digital world.
The Swiss pharma giant reported robust 2025 results, hitting a key profitability goal early. While facing near-term pressure from U.S. generic competition, CEO Vas Narasimhan outlined a strategy anchored by a portfolio of growth brands and a promising late-stage pipeline.
With a $7 billion acquisition and a pipeline focused on convenience, Pfizer is mounting a strategic challenge to Eli Lilly and Novo Nordisk's weight-loss drug stronghold, though commercial impact remains years away.
The British government announces a collaborative initiative with Microsoft and leading experts to develop a national framework for detecting and assessing deepfake content, responding to a surge in AI-generated fraud and abuse.
Healthcare distribution giant McKesson reported robust fiscal third-quarter results, with double-digit growth in revenue and earnings. The company raised its full-year guidance, citing strength in its oncology services and the booming distribution of GLP-1 medications.
Eli Lilly reported a blockbuster 2025 with revenue soaring 45% to $65.2B, fueled by its incretin drugs. Despite anticipating significant pricing headwinds, the company projects 2026 revenue to reach $80-$83B, banking on volume growth from new launches and an expanding late-stage portfolio.
Johnson Controls International (JCI) reported a robust first quarter, exceeding expectations and raising its full-year earnings guidance. The company cited record order growth, particularly in data center and life sciences segments, alongside significant margin expansion. Executives highlighted a record $18 billion backlog but noted timing challenges for near-term revenue conversion.
Publicis Groupe reports robust 2025 growth and a higher dividend, while its ambitious 2026 guidance centers on AI transformation. The market's mixed reaction highlights the tension between the promise of AI-driven efficiency and fears of industry disruption.
SAP's stock has tumbled nearly 38% over the past year, raising questions about its true worth. A deep dive into valuation models suggests the software giant may be significantly undervalued, but investor sentiment remains divided amid broader market pressures.
A recent J.P. Morgan upgrade spotlights Autodesk's strategic shift towards cloud-native platforms and generative AI. While analysts see potential in high-growth sectors like data centers, questions remain about execution and its premium valuation in a competitive market.
Analysts have slightly lowered Wix.com's fair value estimate while nudging up long-term revenue expectations, signaling a nuanced view that balances the company's AI-driven potential against rising costs and execution risks.
Neuroscience analytics firm IXICO appoints industry veteran Tanya Voloshen as its first Chief Commercial Officer, signaling a strategic push to expand its commercial operations and deepen its presence in the critical U.S. market.
With the Pentagon requesting a historic $13.4 billion for artificial intelligence and federal non-defense spending on the rise, data analytics firm Palantir Technologies' deep government ties and accelerating revenue growth position it as a primary beneficiary.
Silver prices tumbled over 9%, wiping out two days of gains amid a broad market pullback. The sell-off extended to gold, tech stocks, and cryptocurrencies as a stronger dollar and sector rotation prompted investors to reassess risk.
As gold and silver prices retreat, the classic signs of a market bubble are undeniable. Yet history shows that identifying a peak is one thing; predicting its collapse is an entirely different challenge for even the most seasoned investors.
A major international study warns that economic models used by governments and investors are dangerously underestimating climate risks, potentially setting the stage for a systemic financial crisis as global temperatures rise.
AppLovin's stock faces significant pressure as new AI-driven competitors emerge and short-sellers raise questions about its financial practices. The launch of Google's Project Genie and the rise of AI-native ad platforms are reshaping the mobile gaming and advertising landscape, prompting investors to reassess the company's growth trajectory.
